nach oben

Erschienen in:

01.02.2011 | Preclinical study

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

verfasst von: Marcus Schmidt, Ilka Brigitte Petry, Daniel Böhm, Antje Lebrecht, Christian von Törne, Susanne Gebhard, Aslihan Gerhold-Ay, Cristina Cotarelo, Marco Battista, Wiebke Schormann, Evgenia Freis, Silvia Selinski, Katja Ickstadt, Jörg Rahnenführer, Martin Sebastian, Martin Schuler, Heinz Koelbl, Mathias Gehrmann, Jan G. Hengstler

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer. We aimed to validate the influence of Ep-CAM RNA expression in untreated node-negative breast cancer. Ep-CAM RNA expression was evaluated utilizing microarray-based gene-expression profiling in 194 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. The prognostic significance of Ep-CAM RNA expression for disease-free survival (DFS), metastasis-free survival (MFS), and breast cancer-specific overall survival (OS) was evaluated in univariate and multivariate analysis adjusted for age, grading, pTstage, ER as well as PR receptor and HER-2 status. Additionally, Ep-CAM RNA expression was compared with immunohistochemistry (IHC) for Ep-CAM in 194 patients. The prognostic impact of Ep-CAM gene expression was validated in further 588 node-negative breast cancer patients. Levels of Ep-CAM RNA expression showed a significant correlation with IHC (P = 0.001) and predicted in univariate analysis DFS (P = 0.001, HR = 2.4), MFS (P = 0.003, HR = 2.5), and OS (P = 0.002, HR = 3.1) accurately. The prognostic influence of Ep-CAM RNA was significant also in multivariate analysis for DFS (P = 0.017, HR = 2.0), MFS (P = 0.049, HR = 1.9), and OS (P = 0.042, HR = 2.3), respectively. The association with MFS was confirmed in an independent validation cohort in univariate (P = 0.006, HR = 1.9) and multivariate (P = 0.035, HR = 1.7) analysis. Ep-CAM RNA correlated with the proliferation metagene (P < 0.001, R=0.425) Nevertheless, in multivariate analysis, Ep-CAM was associated with MFS independent from the proliferation metagene (P = 0.030, HR = 1.8). In conclusion, Ep-CAM RNA expression is associated with poor MFS in three cohorts of untreated node-negative breast cancer.

Nur mit Berechtigung zugänglich

Litvinov SV, Velders MP, Bakker HA et al (1994) Ep-CAM: a human epithelial antigen is a homophilic cell–cell adhesion molecule. J Cell Biol 125:437–446CrossRefPubMed

Naundorf S, Preithner S, Mayer P et al (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101–110CrossRefPubMed

Prang N, Preithner S, Brischwein K et al (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92:342–349PubMed

Amann M, Brischwein K, Lutterbuese P et al (2008) Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 68:143–151CrossRefPubMed

Sebastian M, Kiewe P, Schuette W et al (2009) Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother 32:195–202CrossRefPubMed

Schmidt M, Scheulen ME, Dittrich C et al (2010) An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 21:275–282CrossRefPubMed

Gastl G, Spizzo G, Obrist P et al (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356:1981–1982CrossRefPubMed

Spizzo G, Went P, Dirnhofer S et al (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86:207–213CrossRefPubMed

Hengstler JG, Bockamp EO, Hermes M et al (2006) Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr Cancer Drug Targets 6:603–612CrossRefPubMed

10.

Schmidt M, Hasenclever D, Schaeffer M et al (2008) Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14:5849–5855CrossRefPubMed

11.

Wang Y, Klijn JGM, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMed

12.

Desmedt C, Piette F, Loi S et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207–3214CrossRefPubMed

13.

Loi S, Haibe-Kains B, Desmedt C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246CrossRefPubMed

14.

Schmidt M, Böhm D, von Törne C et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413CrossRefPubMed

15.

McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072CrossRefPubMed

16.

Hengstler JG, Lange J, Kett A et al (1999) Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 59:3206–3214PubMed

17.

Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114CrossRefPubMed

18.

Schmidt M, Hengstler JG, von Törne C et al (2009) Coordinates in the universe of node-negative breast cancer revisited. Cancer Res 69:2695–2698CrossRefPubMed

19.

Sieuwerts AM, Kraan J, Bolt J et al (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101:61–66PubMed

20.

Tanner B, Hasenclever D, Stern K et al (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4317–4323CrossRefPubMed

21.

Trzpis M, McLaughlin PMJ, de Leij LMFH et al (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171:386–395CrossRefPubMed

22.

Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824CrossRefPubMed

23.

Oh DS, Troester MA, Usary J et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664CrossRefPubMed

24.

Dai H, van’t Veer L, Lamb J et al (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65:4059–4066CrossRefPubMed

25.

Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272CrossRefPubMed

26.

Fan C, Oh D, Wessels L et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569CrossRefPubMed

27.

Münz M, Zeidler R, Gires O (2005) The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 225:151–157CrossRefPubMed

28.

Nübel T, Preobraschenski J, Tuncay H et al (2009) Claudin-7 regulates EpCAM-mediated functions in tumor progression. Mol Cancer Res 7:285–299CrossRefPubMed

29.

Ziegler A, Heidenreich R, Braumüller H et al (2009) EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 113:3494–3502CrossRefPubMed

30.

Schmidt D-S, Klingbeil P, Schnölzer M et al (2004) CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res 297:329–347CrossRefPubMed

Titel: Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer
verfasst von: Marcus Schmidt
Ilka Brigitte Petry
Daniel Böhm
Antje Lebrecht
Christian von Törne
Susanne Gebhard
Aslihan Gerhold-Ay
Cristina Cotarelo
Marco Battista
Wiebke Schormann
Evgenia Freis
Silvia Selinski
Katja Ickstadt
Jörg Rahnenführer
Martin Sebastian
Martin Schuler
Heinz Koelbl
Mathias Gehrmann
Jan G. Hengstler
Publikationsdatum: 01.02.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0856-5

Springer Medizin

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Breast cancer in the supraclavicular region: is the horse out of the barn?

Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene

Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL® sample preparation

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Endoscopic breast surgery: where are we now and what might the future hold for video-assisted breast surgery?

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie